Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Reverse Stock Split 1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026 RUTHERFORD, N.J., and LA JOLLA, C.A., October 22, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a

Event · Listing notice
Exchange
Nasdaq
Kind
deficiency
Rule
Nasdaq Listing Rule 5550(a)(2)
Also in this documentStock split

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 22, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GCTK
Neutral
high confidence
Mentioned
$GCTK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GCTKNeutralHigh
01

Why it matters

The split is a corporate action aimed at meeting Nasdaq listing standards; it does not change ownership percentages but may affect liquidity and price perception.

02

Market read

The reverse split is a compliance‑driven corporate action that could modestly affect the stock's price and attract institutional interest.

03

What to watch

Potential dilution from future equity raises and the company's underlying cash burn are not addressed by the split.

Relevance 6/10Novelty 7/10Timing: effective opening of trading on Oct 26, 2026

Background

Glucotrack is a Nasdaq‑listed healthcare technology and biopharma company that previously completed a 1‑for‑15 split in Aug 2026.

Company-level read

Ticker impact

$GCTKNeutralHigh confidence
Context

Glucotrack filed an 8‑K announcing a 1‑for‑2 reverse stock split effective at the open of trading on Oct 26, 2026 to regain Nasdaq $1.00 minimum price compliance.

Expected impact

potential upward pressure as the split lifts price toward the $1.00 threshold

Evidence & confidence

Reverse splits are typically priced in by the market; the primary driver is compliance with Nasdaq listing rules, not fundamental change.

Market effects

May improve perception of micro‑cap biotech/health‑tech sector compliance risk.

Limited to US Nasdaq micro‑cap segment.

Minimal global impact beyond the issuer.

Counterpoint

If the split fails to sustain price above $1.00, the stock could face delisting risk and further decline.

Key entities

  • Glucotrack, Inc.

    Nasdaq‑listed biotech/health‑tech firm executing the reverse split.

  • Nasdaq Hearings Panel

    Granted an exception requiring a $1.00 minimum bid price until Nov 9, 2026.

Related articles

$GCTKHigh

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

$GCTKMed

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKMed

Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

$GLUCMed

Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.